Home › Humacyte Receives Fast Track Designation For HumaGraft For Vascular Access In Hemodialysis Program
 

Keywords :   


Humacyte Receives Fast Track Designation For HumaGraft For Vascular Access In Hemodialysis Program

2014-07-30 10:52:33| drugdiscoveryonline Home Page

Humacyte, Inc., a pioneer in regenerative medicine, has announced that the U.S. Food and Drug Administration (FDA) has designated the HumaGraft development program for vascular access in hemodialysis patients as a Fast Track Development Program

Tags: program access fast track

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
27.11H0599bikke8.7AH
27.11 staff
27.11 TWINS 8oz
27.11
27.1120194
27.11V 7
27.1120th
27.11Under Armour Tactical T /2
More »